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ABSTRACT
Background. The evidence supporting the use of trastuzumab
(T) in a metastatic setting comes from studies that included
(almost) only patients who never received prior T. We investi-
gated the effectiveness of T as first-line therapy for metastatic
breast cancer (mBC) in women previously treated with T in the
adjuvant setting.
Materials and Methods. By using record linkage of five
administrative health care databases of Lombardy, Italy, we
identified 2,046women treatedwith T for early breast cancer
(eBC) in 2006–2009, 96 of whom developed a metastasis
and were retreated with T in first-line treatment for mBC
(treatment group).We compared the overall survival (OS) of
these women with that of 197 women treated with T in first-
line treatment for mBC, who were treated with therapies
other than T for early disease (control group).We computed
Kaplan-Meier 2-year OS and used a proportional hazard
model to estimate the multivariate hazard ratio (HR) of
death in the intervention group compared with the control
group, adjusted by age, use of endocrine therapy, and site
of metastasis.
Results. Two-year OS was 60.0% in the treatment group and
59.5% in the control group. The adjusted HR of death in the
treatment group compared with the control group was 0.79
(95% confidence interval, 0.50–1.26).
Conclusion. Our data provide convincing evidence that the
outcome of women receiving first-line T treatment for mBC
after T failure in the adjuvant setting is comparable to that of
women not receiving T for eBC. These data are of specific
interest, given the unavailability of data from randomized
clinical trials. The Oncologist 2014;19:1209–1215
Implications forPractice: Trastuzumab (T) is the standardof care forHER21breast cancer inmetastatic and early stages, but scant
evidence is availableon its effectiveness as first-linemetastatic treatment inwomenwho failedadjuvant T.Our findings that 2-year
overall survival of women treated with T for early breast cancer and subsequently for metastatic disease is comparable to that of
women treated with Tonly for metastatic disease suggest that T remains effective even after failure in early disease.
INTRODUCTION
HER2 overexpression occurs in 15%–20% of patients with
breast cancer and is associated with aggressive disease and
decreased survival [1]. A number of therapeutic approaches
have been developed against HER2, including monoclonal
antibodies and small molecule tyrosine kinase inhibitors.
Trastuzumab (T), the first anti-HER2 agent, is a humanized
monoclonal antibody that binds to the extracellular, juxta-
membrane portion of the HER2 receptor and suppresses
HER2 signaling activity, resulting in inhibition of downstream
signaling pathways, cell cycle arrest, and a reduction in angio-
genesis [2]. In patients with HER2-amplified metastatic breast
cancer (mBC),Thasantitumoractivity [3, 4], improving survival
in the first-line setting when combined with chemotherapy
[5, 6]. The administration of T in the initial postoperative
(adjuvant) setting, in combination and/or sequentially after
chemotherapy, results in an improvement in disease-free
survival, with a 50% reduction in the risk of relapse, and in
overall survival (OS)ofpatientswithHER2-positiveearlybreast
cancer (eBC) [7, 8].
Despite the advances that have been brought by T, a not
negligible group of patients with HER2-positive eBC who
received adjuvant T therapywill eventually experience disease
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recurrence and will be proposed for treatment in the metastatic
setting.The robustevidencesupporting theuseofT inadjuvant
and metastatic settings comes from studies that primarily
included only patients who never received prior T. Limited
evidence supports the use of T beyond progression inmetastatic
disease [9–11], and no evidence supports its use in patients
with a first relapse who failed adjuvant T. Although it is now
possible to consider different options (lapatinib, pertuzumab,
trastuzumab emtansine) in patients with mBC experiencing
progression of diseasewhile taking T, limited approaches have
been tested for patients who relapse after adjuvant T [12],
and the optimal strategy of therapy for this growing group
of patients remains elusive. However, because T also has been
licensed for eBC, even in the absence of definite evidence, the
daily clinical practice has addressed the problem, and in many
casespatients relapsingafteradjuvantTobtainedretreatment,
mostly in combination with chemotherapy and endocrine
therapy, with variable and unpredictable outcomes.
Therefore, it is important to ascertain the role of T after
failure in an adjuvant setting. In a large cohort of patients who
received T for first-line treatment of metastatic disease, we
compare theOSofwomenwho received or did not receive T in
an adjuvant setting.
MATERIALS AND METHODS
The Italian National Health Service (NHS) provides universal
coverage with standard care to all Italian citizens. Reimburse-
ment to hospitals and other health care providers is performed
through administrative health care databases at the regional
level. T was first approved in Italy for HER21 mBC and in July
2006 for eBC [13]. T is dispensed by hospital pharmacies only,
and since January 2006 in Lombardy, it is mandatory to register
each dispensation in a special file (File F). In previous work, we
builtacohortofmorethan2,000womenwhohadusedTforeBC
by record linkage of several regional administrative health care
databases, and we analyzed cardiotoxicity [14] and estimated
OS and progression-free survival [15, 16] in clinical practice.
Data Sources
Five regional health administrative databases were used: (a)
the File F registry 2006–2009, in which any administration of T
reimbursed by the NHS has been mandatorily recorded since
2006; (b) the regional hospital discharge forms (Scheda di
Dimissione Ospedaliera [SDO]) database (1997–2010); (c) the
Outpatients’ Services database (2002–2010); (d) the Registry
Office database of Lombardy, updated to April 2011; and (e)
the drug prescription database.
Patient Identification by the Same Unique Anonymous
Code in All Databases
A more detailed description of the databases used for the
record linkageandof theoperativeproceduresused to identify
the various groups of women are given in supplemental
Appendix 1 and previous publications [14, 16].
Selection of Intervention and Control Groups
We carried out a computerized record linkage through the
unique anonymous patient identification code. We selected
all women who resided in Lombardy, who were first treated
with T between August 2006 and December 2009, and who
had a SDO reporting a breast cancer diagnosis before the
first T administration. By comparing the dates of the first SDO
reporting a breast cancer diagnosis, the first SDO reporting a
metastasis, andthe firstTadministration,wedivided theminto
(a) women first treated with T for eBC and (b) women treated
with T for mBC only. We excluded women for whom we could
not determine whether the first T treatment was for eBC or mBC
(supplemental Appendix 1 shows the operative definitions).
Amongwomen treated with T for eBC, we identified those
who developed a metastasis and restarted or continued T
treatment after the metastasis. We further excluded women
who did not receive T for mBC as first-line treatment.
Therefore, the “treatment group” consisted of women who
were treated with T for eBC and were treated again with T as
first-line therapy (supplemental Appendix 1 shows the
operative definitions) for mBC (mBC/adjT1).
For the control group, we selected patients treated with T
for mBC only.We excluded patients with “up-front metastatic
disease” from the control group, that is, womenwhowere not
previously treated for eBCwith a therapyother than T.We also
excluded women treated with T for mBC, but not as first-line
therapy. Therefore, the “control group” consisted of women
who were treated for eBC, but not with T, and were treated




formBC to death fromany cause (from the SDOdatabase and/
or the Registry Office database). Patients were followed up
until death or April 30, 2011,whichever came first. Differences
in OS curves were tested by the log-rank test [17].
Wealso estimated thehazard ratio (HR) ofdeathofwomen
previously treatedwith T for eBC (mBC/adjT1) comparedwith
women treatedwith T formBC only (mBC/adjT2), adjusted by
age (,50,50–59,60–69,701years), useofendocrine therapy,
and site of metastasis (brain, liver/lung, other), using Cox
proportional hazards models [17]. The proportional hazard
assumption was assessed by both plotting minus log(log
(survival function)) versus log(time) and using the analytic
methodbasedoncomparisonbetweenobservedresidualsand
a randomly generated sample process (Kolmogorov-type
supremum test) [17].
Wealso compared the survival ofwomen treatedwithT for
eBC who did and did not restart or continue the treatment for
themetastatic disease. In this case, OSwas defined as the time
from the diagnosis of metastasis to death from any cause or
end of follow-up.
RESULTS
Figure 1 presents a flowchart of the selection of the treatment
and control groups. Overall, 2,879 patients received the first T
prescription between August 2006 and December 2009. We
excluded 9men and 143 womenwith inconsistent data, or for
whomwe could not define whether Twas first used for eBC or
mBC. Of the 2,046 women first treated with T for eBC, 240
developed distant recurrence after the beginning of treat-
ment; 113 did not use T after the diagnosis of metastasis,
whereas 127 continued or restarted the therapy, 96 of whom
received T as first-line treatment for mBC (“treatment group,”
©AlphaMed Press 2014
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mBC/adjT1). Compared with women who continued or
restarted T (n 5 127), those who did not receive T after the
diagnosis of the metastasis (n 5 113) were older (26.6% vs.
10.2% aged $70 years) and more frequently had brain
metastases (34.5% vs. 9.5%) (supplemental online Table 1).
One year after metastasis, OS was 39.8% in women who
did not restart T and 88.0% in women who did. In the 96
women included in the treatment group, 64 (67%) of the
metastases occurred during orwithin 6months since stopping
T treatment.
A total of 681 women first received T for mBC only. After
exclusion of 212 women who had “up-front metastatic
disease” and a further 272 women who received T for mBC
notas first-line therapy,thecontrolgroup included197women
who received T as first-line treatment for mBC and were
treated with therapies other than T for eBC (mBC/adjT2).
Table 1 shows the age and the site of metastasis of 96 T
users for eBC and subsequent first-line treatment for mBC
(mBC/adjT1, treatment group) and of 197 Tusers for first-line
treatment for mBC only (mBC/adjT2, control group), exclud-
ing women with “up-front metastatic disease.”Women in the
treatment group were younger (41.7% vs. 23.8% aged ,50
years) and more frequently had brain metastases (9.4% vs.
4.1%) thanwomen in the control group.Themedian follow-up
was 2.5 years. Survival estimates for the treatment groupwere
87.5% after 1 year of follow-up and 60.0% after 2 years of
follow-up; corresponding figures for the control group were
80.6% and 59.5%, respectively (Fig. 2).
Table 2 presents the results of the proportional hazard
model, including terms for age, use of endocrine therapy,
metastatic site, and treatment/control group. No significant
difference emerged with age. Compared with women with
brain metastases, those with liver and lung metastases had
a lower hazard ofdying (HR, 0.28; 95%confidence interval [CI],
0.14–0.54), and thosewith onlymetastases at sites other than
thebrain, liver, or lunghadaneven lower risk (HR, 0.13; 95%CI,
0.07–0.27). The HR of death in the treatment group (mBC/
adjT1) compared with the control group (mBC/adjT2),
Figure 1. Flowchart describing the selection of the treatment and control groups from the cohort of women treated with T for breast
cancer.
Abbreviations: AdjT, adjuvant trastuzumab; eBC, early breast cancer; mBC, metastatic breast cancer; T, trastuzumab.
www.TheOncologist.com ©AlphaMed Press 2014
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adjusted by age, history of endocrine therapy, and metastatic
site,was0.79 (95%CI, 0.50–1.26), similar to theunadjustedHR
(0.86; 95% CI, 0.55–1.34).
DISCUSSION
Our study reports the OS of a cohort of patients with mBC,
treated with first-line T-based combination therapy, who
received or did not receive T in an adjuvant setting. Of 293
patients with mBC who received T as first-line treatment, the
96 women treated with T for eBC and retreated for metastatic
disease showed anOS that was similar to the 197womenwho
received T for mBC only, that is, not treated with T before the
diagnosis ofmetastasis (60% inboth groups after2 years;HRof
death, 0.79; 95% CI, 0.50–1.26).
T is the well-established mainstay treatment of women
affected by HER21 breast cancer. The effectiveness of T has
been widely demonstrated in both adjuvant and metastatic
HER21 breast cancer, and some observations suggested
a potential role of T beyond disease progression [9–11, 18].
According to this evidence,Thasbeenpredicted tobeeffective
in the first-line settingofmBCafterTadjuvant failure.Although
novel potential anti-HER2optionshavebeendeveloped, at the
present time, the retreatment of patients with metastatic
cancer with T still represents a widely used option, notwith-
standing that the clinical impact of such a strategy has never
been formally ascertained in controlled randomized clinical
trials (RCTs).
The Italian guidelines for breast cancer treatment (Asso-
ciazione ItalianadiOncologiaMedica [AIOM]2012) [19] advise
to restart T in association with chemotherapy (taxanes,
vinorelbine, capecitabine) as first-line treatment of mBC in
women treated with T in the adjuvant setting. The level of
evidence of this recommendation is rated on the basis of
expertopinionalone, that is,withoutanysupport fromanalytic
studies, and the strength of this recommendation is rated as
weak positive, adapted from theGRADEmethod [20].TheU.S.
National Comprehensive Cancer Network (NCCN) guidelines
accept taxotere, trastuzumab, and pertuzumab as the pre-
ferred first-line therapy for patients with metastatic HER21,
including patients who received prior trastuzumab in the
adjuvant setting (NCCN 2014) [21]. The National Institute for
Health and Clinical Excellence 2009 guidelines [22] do not
specifically address the problem, but suggest discontinuation
of T for mBC in case of disease progression outside the central
nervous system. Thus, there are different attitudes, reflecting
the lack of solid data on the matter, in the absence of
information generated from dedicated clinical trials. At the
same time, it is unlikely that such trials will be launched in the
near futurebecauseof theevidentethical andclinical concerns
these investigations would implicate. Consequently, informa-
tion in this field ismostly confined to retrospective studies and
post hoc subgroup analyses of existing datasets.
This uncertainty also is reflected by the fact that of the 240
women who developed a metastasis while treated with T for
eBC, 127 (53%)were retreatedwith T and 113 (47%)were not.
This isnot surprisinggiven the lackofsolidevidenceaboutTuse
in this context, particularly at the time of the study. Older age,
comorbidities, and the presence of a brain metastasis were
strong predictors for not receiving T formBCafter failure in the
adjuvant setting inourdata.There is strongevidence thatolder
patients areundertreated [23].Moreover, the cardiotoxicityof
T [14] has likely discouraged its use in women at high risk of
cardiac disease, as did the presence of a brain metastasis, for
which the use of T has been debated [24, 25].
An issue to bear in mind is that because of the short
timeframeof this studyand the introduction of adjuvant Tonly
inmid-2006 in Italy,twothirdsof thewomenwhoreceivedTfor
both eBC and mBC were refractory to T, that is, developed
a metastasis during T treatment or within 6 months from
stopping T treatment. Thus, our cohort is mostly composed of
women forwhom the response to T in the adjuvant setting has
beenworse, at least in termsofefficacy.Thus, strictly speaking,
our results do not apply to women who develop a metastasis
long after stopping T for eBC, although thesewomen should, if
anything, have a better prognosis than the women in our
treatment group.
The control group was not treated with the most effective
therapy in the beginning. However, the use of T in the adjuvant
setting was authorized in Italy in mid-2006; thus, women with
a HER21 early breast cancer in the few years before that
date were not treated with T. Moreover, T-na¨ıve women are
exactly those for whom the efficacy of T for mBC has been
demonstrated.
Ourdataareconsistentwith those recently reported in two
RCTs, partially focusing on the same theme as our study. First,
the CLEOPATRA RCT, while comparing first-line pertuzumab,
trastuzumab, and docetaxel with placebo, trastuzumab, and
docetaxel for HER21 mBC, included 80 patients with mBC
(10% of the entire study population) in the analysis who were
treated with T in the neoadjuvant/adjuvant setting [26]. In
Table 1. Age, use of endocrine therapy, and site of metastasis
among 96 women treated with T for both early breast cancer
(eBC) and mBC as first line of therapy (mBC/adjT1), and 197
women treated with other therapies for eBC and first-line T
therapy for mBC (mBC/adjT2)
mBC/adjT1 96 mBC/adjT2 197
n % n %
Agea (yrs)
,40 11 11.5 16 8.1
40–49 29 30.2 31 15.7
50–59 25 26.0 48 24.4
60–69 20 20.8 57 28.9
$70 11 11.5 45 22.8
p for heterogeneity .009
Use of endocrine therapy
No 54 56.3 88 44.7
Yes 42 43.7 109 55.3
p for heterogeneity .063
Metastatic site
Brain 9 9.4 8 4.1
Liver/lung 42 43.7 107 54.3
Other 45 46.9 82 41.6
p for heterogeneity .083
aAge at first trastuzumab prescription for metastatic breast cancer.
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a post hoc subgroup analysis, the favorable effect on OS of
adding pertuzumab to T and docetaxel in women previously
treatedwith T (HR, 0.68; 95%CI, 0.30–1.55)was similar to that
for the whole intention-to-treat population (HR, 0.69; 95% CI,
0.58–0.81). However, the authors did not compare the OS of
women previously treated with T with those who were not.
Figure 2. Kaplan-Meier estimates of overall survival among 96women treatedwith T for both eBC andmBCas first line of therapy (mBC/
adjT1) and 197 women treated with other therapies for eBC and first-line T therapy for mBC (mBC/adjT2).
Abbreviations: AdjT, adjuvant trastuzumab; eBC, early breast cancer; mBc, metastatic breast cancer.
Table 2. Estimated HR and corresponding 95% CIs frommultivariate Coxmodel among 197 women treated with other therapies
for early breast cancer (eBC) and first-line T therapy formBC (mBC/adjT2), and 96women treatedwith T for both eBC andmBC as
first line of therapy (mBC/adjT1)
No. No. (%) of events HRa (95% CI)
Group
mBC/adjT2 197 77 (39.1) 1b
mBC/adjT1 96 26 (27.1) 0.79 (0.50–1.26)
Age, yrs
,70 237 82 (34.6) 1b
$70 56 21 (37.5) 1.16 (0.98–1.37)
Use of endocrine therapy
No 142 63 (44.4) 1b
Yes 151 70 (46.4) 0.87 (0.59–1.29)
Metastatic site
Brain 17 12 (70.6) 1b
Liver/lung 149 63 (42.3) 0.28 (0.14–0.54)
Other 127 28 (22.1) 0.13 (0.07–0.27)
aEstimated by multivariate Cox model adjusted by intervention group, age, use of endocrine therapy, and metastatic site.
bReference category.
Abbreviations: AdjT, adjuvant trastuzumab; CI, confidence interval; HR, hazard ratio; mBC, metastatic breast cancer.
www.TheOncologist.com ©AlphaMed Press 2014
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Second, a nonrandomized, multicenter, open-label phase II
study in mBC (Retreatment after HErceptin Adjuvant [RHEA]
trial) reportedanencouragingactivityofT inpreviously treated
eBC [27]. Indeed, the RHEA study investigated the efficacy and
safety of Tplus a taxane in patients who experienced a relapse
after adjuvant T. For the 41 included patients, partial response
was observed in 25 (61%), and median progression-free
survivalwas8.0months [27].To thebestofour knowledge, this
retrospective analysis represents the most extensive study
exploring the effectiveness of T after adjuvant failure.
Given the lack of data from RCTs on this issue, our study
offersavaluablecontribution,despite its limitations.Ourstudy
is based on record linkage of administrative databases, and
therefore it is conceivable that some misclassification in
defining the various groups has occurred. The fact that our
cohort ofwomen treatedwith T for eBChad anOS comparable
to that of the HERceptin Adjuvant trial [16, 28] is reassuring
against substantial misclassification of T treatment for mBC as
eBC.Another limitation is the lackofdetailed clinical information,
which also prevented the evaluation of progression-free survival
in our cohort of patients.
Moreover, given the “real-world” nature of our data [15,
29], themodes of patients’metastaticworkup atdiagnosis and
follow-upwereheterogeneous.The Italianguidelines, fromthe
National Society ofMedical Oncology (AIOM), provide regular
recommendations for tumorassessmentat the timeof the first
breast cancer diagnosis. Because the population is derived
exclusively from the Lombardy region, we do have reasons to
expect a consistent approach in this population regarding the
diagnosticmetastatic workup.The retrospective nature of this
observation and the sources of our database prevented us
from obtaining a centralized assessment of HER2 status.
However, our analysis moved fromdrug (T) rather than cancer
subtype (HER2), and the criteria for patients’ enrollment were
based on T administration. We have discussed the problem
of the quality of HER2 status ascertainment in a previous
article [14]. However, there is no reason why the quality of
ascertainment of HER2 status should differ between our two
groups. Thus, these potential limitations do not attenuate the
messageofTeffectivenessemerging fromtheOSanalysis. If, as
the evidence fromRCTs shows,T is effective in T-na¨ıve women
treated for mBC, then our results indicate that it is also
effective after T failure in the adjuvant setting, and to
approximately the same extent.
CONCLUSION
Given the lack of data from RCTs, our study provides the
strongest evidence that the outcomeofwomen receiving first-
line T treatment formBC after T failure in an adjuvant setting is
comparable to that of women not exposed to T during eBC
therapy.
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For Further Reading:
Francisco J. Esteva, Sandra X. Franco,Maura K. Hagan et al. An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus
Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer. The Oncologist 2013;18:661–666.
Implications for Practice:
Dual targeting of the HER2 receptor using trastuzumab and lapatinib has been shown to be effective in HER2-positive
metastatic breast cancer. In this study,we evaluated the safety of paclitaxel in combinationwith trastuzumab and lapatinib.
The main side effect was diarrhea, which occurred in the majority of patients at the standard dosing of all three drugs. A
pharmacokinetic interactionwas found betweenpaclitaxel and lapatinib, resulting in increased exposureof both drugs.We
evaluated three dose levels of lapatinib and paclitaxel (all patients received standard trastuzumab dosing). A dose of
lapatinib 750 mg/day had the lowest incidence of diarrhea in combination with paclitaxel 80 mg/m2 per week and
trastuzumab 2mg/kg per week.These doses should be used if the triplet is considered for further development in patients
with HER2-positive metastatic breast cancer.
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